Alembic Pharmaceuticals Limited (BOM:533573)
India · Delayed Price · Currency is INR 949.60
+14.55 (1.56%)
At close: Aug 11, 2025
Alembic Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade |
Depreciation & Amortization | - | 2,786 | 2,727 | 2,754 | 2,868 | 1,835 | Upgrade |
Other Amortization | - | - | - | 984.4 | 801.3 | - | Upgrade |
Loss (Gain) From Sale of Assets | - | -32.6 | -17 | 47 | -5.4 | -13.9 | Upgrade |
Loss (Gain) From Sale of Investments | - | -4 | -27.6 | -1.4 | - | -13.3 | Upgrade |
Loss (Gain) on Equity Investments | - | -8.7 | 9.8 | 309.2 | -52.8 | - | Upgrade |
Provision & Write-off of Bad Debts | - | 34.6 | 53.6 | - | 73 | 60.6 | Upgrade |
Other Operating Activities | - | 1,484 | 84.8 | 301.7 | 303.6 | -1,082 | Upgrade |
Change in Accounts Receivable | - | -3,950 | 390.5 | -2,229 | -4,696 | 5,109 | Upgrade |
Change in Inventory | - | -6,446 | -1,683 | 1,344 | -1,236 | -2,986 | Upgrade |
Change in Accounts Payable | - | 1,462 | 560.4 | -281.7 | 366.7 | 452.7 | Upgrade |
Change in Other Net Operating Assets | - | -279.1 | -224.6 | 590.5 | 1,892 | -192.8 | Upgrade |
Operating Cash Flow | - | 879.7 | 8,032 | 7,240 | 5,524 | 14,634 | Upgrade |
Operating Cash Flow Growth | - | -89.05% | 10.95% | 31.07% | -62.26% | 225.82% | Upgrade |
Capital Expenditures | - | -5,636 | -3,275 | -4,434 | -4,256 | -6,595 | Upgrade |
Sale of Property, Plant & Equipment | - | 97.7 | 115.6 | 18.7 | 13.9 | 2.7 | Upgrade |
Investment in Securities | - | -211.3 | - | -70 | 476.8 | -1,861 | Upgrade |
Other Investing Activities | - | 65.7 | -47 | 9.5 | 46 | 65.3 | Upgrade |
Investing Cash Flow | - | -5,684 | -3,206 | -4,476 | -3,720 | -8,388 | Upgrade |
Short-Term Debt Issued | - | 7,651 | - | 2,059 | 4,300 | - | Upgrade |
Total Debt Issued | - | 7,651 | - | 2,059 | 4,300 | - | Upgrade |
Short-Term Debt Repaid | - | - | -2,054 | - | - | -8,605 | Upgrade |
Long-Term Debt Repaid | - | -265.6 | -258.2 | -2,231 | -3,202 | -3,980 | Upgrade |
Total Debt Repaid | - | -265.6 | -2,312 | -2,231 | -3,202 | -12,585 | Upgrade |
Net Debt Issued (Repaid) | - | 7,386 | -2,312 | -172.3 | 1,098 | -12,585 | Upgrade |
Issuance of Common Stock | - | - | - | - | - | 7,341 | Upgrade |
Common Dividends Paid | - | -2,162 | -1,573 | -1,966 | -2,752 | - | Upgrade |
Other Financing Activities | - | -786.3 | -493.9 | -481.7 | -519.7 | -730.4 | Upgrade |
Financing Cash Flow | - | 4,437 | -4,379 | -2,620 | -2,174 | -5,974 | Upgrade |
Foreign Exchange Rate Adjustments | - | - | - | - | - | -9.3 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | 0.1 | -0.1 | - | 0.1 | Upgrade |
Net Cash Flow | - | -367.3 | 447.3 | 143.9 | -369.7 | 262.2 | Upgrade |
Free Cash Flow | - | -4,757 | 4,757 | 2,805 | 1,267 | 8,039 | Upgrade |
Free Cash Flow Growth | - | - | 69.58% | 121.40% | -84.24% | - | Upgrade |
Free Cash Flow Margin | - | -7.13% | 7.64% | 4.96% | 2.39% | 14.90% | Upgrade |
Free Cash Flow Per Share | - | -24.20 | 24.20 | 14.27 | 6.45 | 41.49 | Upgrade |
Cash Interest Paid | - | 785.9 | 493.7 | 497 | 519.2 | 729.4 | Upgrade |
Cash Income Tax Paid | - | 714 | 198.5 | 607 | 1,234 | 2,454 | Upgrade |
Levered Free Cash Flow | - | -7,272 | 2,198 | 504.46 | -324.73 | 4,359 | Upgrade |
Unlevered Free Cash Flow | - | -6,780 | 2,549 | 818.03 | -213.91 | 4,459 | Upgrade |
Change in Working Capital | - | -9,214 | -956.5 | -575.6 | -3,673 | 2,383 | Upgrade |
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.